PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Open Access
- 30 March 2025
- journal article
- review article
- Published by Elsevier in Translational Oncology
- Vol. 55, 102366
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (SCHN 959/7-1, SCHN 959/3-2, KFO5002)
This publication has 43 references indexed in Scilit:
- First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationAnnals of Oncology, 2024
- KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screeningMolecular Oncology, 2024
- A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancerCell Chemical Biology, 2024
- A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutationsESMO Open, 2024
- Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistanceCancer Cell, 2023
- KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cellsCancer Cell, 2023
- 456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumorsAnnals of Oncology, 2022
- Pharmacologic modulation of RNA splicing enhances anti-tumor immunityCell, 2021
- Protein Arginine Methyltransferase 5 in T Lymphocyte BiologyTrends in Immunology, 2020
- MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 AxisCell Reports, 2016